CLINICAL_TRIALS
trial_result
· 2025-07-11
Clinical Trial Update: Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Summary
Phase 1 study of KITE-222 in relapsed/refractory acute myeloid leukemia has been terminated with trial results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kite, A Gilead Company | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2025-07-11